possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices'' (12 U.S.C. 1843). Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 29, 1996.

A. Federal Reserve Bank of Minneapolis (Karen L. Grandstrand, Vice President) 250 Marquette Avenue, Minneapolis, Minnesota 55480:

*1. Norwest Corporation*, Minneapolis, Minnesota; to engage *de novo*, as a joint venture, through its subsidiary, Central Federal Mortgage Company, State College, Pennsylvania, in residential mortgage lending business, pursuant to § 225.25(b)(1) of the Board's Regulation Y. The co-venturers will be Norwest Ventures, Inc., Minneapolis, Minnesota and Centre Professionals, Inc. d/b/a RE/MAX Centre Realty, State College, Pennsylvania.

Board of Governors of the Federal Reserve System, October 8, 1996.

Jennifer J. Johnson

*Deputy Secretary of the Board*

[FR Doc. 96–26264 Filed 10-11-96; 8:45 am]

**BILLING CODE 6210-01-F**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Agency for Health Care Policy and Research; Agency Information Collection Activities: Submission for OMB Review; Comment Request

**AGENCY:** Agency for Health Care Policy and Research.

**ACTION:** Emergency clearance notice.

**SUMMARY:** This notice announces the Agency for Health Care Policy and Research's (AHCPR) intention to request the Office of Management and Budget (OMB) to reinstate two expired information collection projects as one: Formerly the 1987 Health Insurance Plans Survey (HIPS) and the 1994 National Employer Health Insurance Survey (NEHIS), now to be combined in the 1997 Medical Expenditure Panel Survey—Insurance Component (MEPS–IC). In accordance with the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3507(a)(1)(D)), AHCPR invites the public to comment on this reinstatement.

In further compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. 3507(j)(1)(A)(i)), AHCPR has submitted to the OMB a request for Emergency Review. This review is requested because collection of this information is needed prior to the expiration of the normal time limits under OMB's regulations at 5 CFR 1320.13, in order to allow for the information collection project: Pretest for the 1997 Medical Expenditure Survey—Insurance Component (MEPS–IC).

The pretest was somewhat delayed as the Department worked to achieve efficiencies by consolidating the two previous surveys under DHHS's Survey Integration Plan. The pretest is now underway and it is urgent that it not be interrupted in order to assure the quality and integrity of the pretest data. The MEPS–IC is scheduled to begin in April 1997 when employers have information readily available on health plans, which are generally offered and processed on an annual basis. Delays in the pretest results will cause resulting delays in the overall MEPS–IC survey, which is the only national level effort to collect information on the supply of private health insurance available to American workers, including annual premium expenditures, benefits paid, and administrative costs for national health accounts, maintained by HCFA. This information, along with that from the larger MEPS-Household Component, is important for evaluating current and proposed health policies by both the private and public sectors.

**DATES:** AHCPR is requesting that OMB provide a 2-day review and a 90-day approval. During this 90-day period AHCPR will publish a separate Federal Register notice to provide a 30-day public review and comment period on these requirements.

**ADDRESSES:** Written comments for the proposed information collection should be submitted within 2 working days of this notice directly to the OMB Desk Officer at the following address: Allison Eydt, Human Resources and Housing Branch, Office of Information and Regulatory Affairs, OMB; New Executive Office Building, Room 10235; Washington, D.C. 20503.

All comments will become a matter of public record.

**FOR FURTHER INFORMATION CONTACT:** Ruth A. Celtnieks, AHCPR Reports Clearance Officer, (301) 594–1406, ext. 1497.

**SUPPLEMENTARY INFORMATION:** AHCPR intends to conduct a survey of establishments in 1997 to collect information from employers concerning employer-sponsored health insurance. This survey will be an integration of two previous surveys, now components of MEPS–IC. The two surveys which collected similar information are:

1. The 1987 Health Insurance Plans Survey sponsored by AHCPR's predecessor, the National Center for Health Services Research; and

2. The 1994 National Employer Health Insurance Survey sponsored by AHCPR, the National Center for Health Statistics (NCHS) and the Health Care Financing Administration (HCFA). Due to the integration of these two previous survey operations into the MEPS–IC, AHCPR is updating the questionnaire and data collection methodology. A data collection pretest is being proposed using a sample of potential respondents. Based upon the results of this test, the AHCPR will develop and refine the final methodology for the 1997 MEPS–IC.

*Burden Estimates Follow:*

Number of Respondents—350.

Number of Surveys per Respondent—1.

Average Burden/Respondent—.75 Hours.

Estimated Total Burden—263 Hours.

Copies of these data collection plans and instruments can be obtained from the AHCPR Reports Clearance Officer (see above).

Dated: October 7, 1996.

Clifton R. Gaus,

*Administrator.*

[FR Doc. 96–26302 Filed 10–11–96; 8:45 am]

**BILLING CODE 4160–90–M**

## Centers for Disease Control and Prevention

### The National Institute for Occupational Safety and Health; Meeting

*Name*: Review of proposed protocol for the study: ''A Cohort Mortality Study with a Nested Case-control Study of Lung Cancer and Diesel Exhaust Among Non-metal Miners.''

*Time and date:* 9 a.m-3 p.m., November 8, 1996.

*Place:* National Cancer Institute (NCI), Conference Room H, Executive Plaza North, 6130 Executive Boulevard, Rockville, Maryland 20892.

*Status:* Open to the public for observation and participation, limited only by the space available. The meeting room accommodates approximately 50 people.

*Purpose:* The purpose of this meeting is to obtain comments and guidance

regarding the technical and scientific merits of the study: ''A Cohort Mortality Study with a Nested Case-control Study of Lung Cancer and Diesel Exhaust Among Non-metal Miners,'' being conducted jointly by NIOSH and NCI.

*Matters to be Discussed:* Agenda items include short presentations concerning the study protocol by the study investigators, comments from the Review Panel members, responses and discussion of comments submitted by others who have reviewed the protocol, and discussion open to all meeting attendees. Viewpoints and suggestions from industry, labor, academia, other government agencies, and the public are invited. Written comments will be part of the review, and should be received by the contact person listed below no later than November 1, 1996. Agenda items are subject to change as priorities dictate.

*Contact Person for More Information:* Michael Attfield, Ph.D., NIOSH Project Director, Division of Respiratory Disease Studies, M/S 234, 1095 Willowdale Road, Morgantown, West Virginia 26505–2888, telephone 304/285–5751, fax 304/285–5861.

Dated: October 8, 1996.

Nancy C. Hirsch,

*Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 96–26300 Filed 10–11–96; 8:45 am]

BILLING CODE 4160–19–M

## Food and Drug Administration

**[Docket No. 96F–0370]**

## Dover Chemical Corp.; Filing of Food Additive Petition

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that Dover Chemical Corp. has filed a petition proposing that the food additive regulations be amended to provide for the safe use of 3,9-bis[2,4-bis(1-methyl-1-phenylethyl) phenoxy]-2,4,8,10-tetraoxa-3,9-diphosphaspiro[5.5]undecane as an antioxidant and/or stabilizer for olefin polymers intended for use in contact with food.

**DATES:** Written comments on the petitioner's environmental assessment by November 14, 1996.

**ADDRESSES:** Submit written comments to the Dockets Management Branch (HFA–305), Food and Drug Administration, 12420 Parklawn Dr., rm. 1–23, Rockville, MD 20857.

**FOR FURTHER INFORMATION CONTACT:** Vir D. Anand, Center for Food Safety and Applied Nutrition (HFS–216), Food and Drug Administration, 200 C St. SW., Washington, DC 20204, 202–418–3081.

**SUPPLEMENTARY INFORMATION:** Under the Federal Food, Drug, and Cosmetic Act (sec. 409(b)(5) (21 U.S.C. 348(b)(5))), notice is given that a food additive petition (FAP 6B4521) has been filed by Dover Chemical Corp., 3676 Davis Rd. NW., Dover, OH 44622. The petition proposes to amend the food additive regulations in § 178.2010 *Antioxidants and/or stabilizers for polymers* (21 CFR 178.2010) to provide for the safe use of 3,9-bis[2,4-bis(1-methyl-1-phenylethyl) phenoxy]-2,4,8,10-tetraoxa-3,9-diposphaspiro[5.5]undecane as an antioxidant and/or stabilizer for olefin polymers intended for use in contact with food.

The potential environmental impact of this action is being reviewed. To encourage public participation consistent with regulations promulgated under the National Environmental Policy Act (40 CFR 1501.4(b)), the agency is placing the environmental assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before November 14, 1996 submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the Federal Register. If, based on its review, the agency finds that an environmental impact statement is not required and this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the Federal Register in accordance with 21 CFR 25.40(c).

Dated: October 2, 1996.

Alan M. Rulis,

*Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.*

[FR Doc. 96–26372 Filed 10–11–96; 8:45 am]

BILLING CODE 4160–01–F

**[Docket No. 94E–0099]**

## Determination of Regulatory Review Period for Purposes of Patent Extension; Neutrexin™; Correction

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice; correction.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting the notice that appeared in the Federal Register of August 30, 1994 (59 FR 44737). The document announced FDA's determination of the regulatory review period for purposes of patent extension for Neutrexin™ (trimetrexate glucuronate). The document was published with an error in one of the dates stated as part of the regulatory review period and requires additional clarification between the patent extension applicant's records and FDA's records.

**FOR FURTHER INFORMATION CONTACT:** Brian J. Malkin, Office of Health Affairs (HFY–20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–1382.

In FR Doc. 94–21280, appearing on page 44737 in the Federal Register of Tuesday, August 30, 1994, the following corrections are made:

On page 44737, in the second column, in the second complete paragraph, in the fourth line, ''1,934'' is corrected to read ''1,931''; and in the sixth line, ''317'' is corrected to read ''320''; in the same column, in the third complete paragraph, in the eighth line, ''However,'' is removed; in the eleventh line, ''March 10, 1987. FDA'' is corrected to read ''March 10, 1987. The applicant has documentation to suggest that an FDA official orally removed IND 29,796 from clinical hold on September 2, 1987. However, FDA''; in the fourteenth line, ''clinical hold'' is corrected to read ''clinical hold via letter''; and in the same column, in the last paragraph, beginning in the fifth line, ''February 4, 1993'' is corrected to read: ''February 1, 1993''; and the last two sentences are corrected to read: ''FDA has verified the applicant's claim that the new drug application (NDA) for Neutrexin™ (NDA 20–326) was initially submitted on February 1, 1993.''

Dated: October 8, 1996.

Stuart L. Nightingale,

*Associate Commissioner for Health Affairs.*

[FR Doc. 96–26301 Filed 10–11–96; 8:45 am]

BILLING CODE 4160–01–F